pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Capecitabine
drug
save

capecitabine

Marketedupdated 3mo ago
by Armas Pharmaceuticals Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • tagApproval72 co-mentions · 36 sources
  • tagSmall Molecule36 co-mentions · 36 sources
  • tagOncology7 co-mentions · 3 sources
  • tagColorectal Cancer2 co-mentions · 2 sources
  • companyJapanese Governmental Office1 co-mentions · 1 sources
  • companySun Yat-sen Memorial Hospital1 co-mentions · 1 sources
  • companyCancer Institute and Hospital Chinese Academy of Medical Sciences1 co-mentions · 1 sources

indications

investigational
Colorectal Cancer

all catalysts(3)

phase 2 completion · 2
Apr 24, 2026
phase 2 completion
4mo ago
Japanese Governmental Office — capecitabine (Phase II Trial Completion)
capecitabine
→
Apr 30, 2026
phase 2 completion
4mo ago
Cancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)
capecitabine
→
phase 3 completion · 1
Apr 28, 2026
phase 3 completion
4mo ago
Sun Yat-sen Memorial Hospital — capecitabine (Phase III Trial Completion)
capecitabine
→

Trials studying capecitabine

  • phase2A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinomarecruitingn=100
  • phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)recruitingn=2,400
  • phase3Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)recruitingn=1,530
  • phase3A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)recruitingn=1,000
  • phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Canceractive not recruitingn=138
  • phase3A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancerrecruitingn=500
  • phase2A Study of MRG007 Combination Therapy for Advanced Colorectal Cancernot yet recruitingn=316
  • phase1Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancerrecruitingn=60
more trials →

News(1)

  • Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
    Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.
    fiercebiotech · 19d ago
brand
Capecitabine
generic
capecitabine
indication
Colon Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?